Wall Street Zen upgraded shares of Azul (NYSE:AZUL – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.
A number of other brokerages have also recently issued reports on AZUL. BWS Financial restated a “buy” rating and issued a $20.00 target price on shares of Azul in a report on Monday, September 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Azul in a research report on Tuesday, October 6th. Deutsche Bank Aktiengesellschaft began coverage on Azul in a report on Wednesday, September 9th. They set a “buy” rating and a $11.00 target price for the company. The Goldman Sachs Group started coverage on Azul in a research report on Monday, October 19th. They issued a “neutral” rating and a $8.10 price target for the company. Finally, Zacks Research raised Azul from a “strong sell” rating to a “hold” rating in a research note on Friday, October 16th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $13.03.
View Our Latest Analysis on AZUL
Azul Trading Down 32.4%
NYSE AZUL opened at $4.07 on Friday. Azul has a 1 year low of $3.90 and a 1 year high of $495.00. The firm has a fifty day moving average of $7.05.
Azul Company Profile
Azul SA, through its principal subsidiary Azul Linhas AƩreas Brasileiras SA, is a Brazilian airline that provides scheduled passenger air transportation and air cargo services. The company serves business and leisure travelers, offering flights across Brazil and to selected international destinations.
Azul operates a broad domestic network connecting major Brazilian cities with regional communities. Its international service includes destinations in South America, the United States and Europe, with routes and schedules subject to change.
Featured Articles
- Five stocks we like better than Azul
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Azul Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azul and related companies with MarketBeat.com's FREE daily email newsletter.
